ArticleAcademic radiology2025
Assessing the Reliability of Pancreatic CT Imaging Biomarkers for Diabetes Prediction: A Dual Center Retrospective Study.
Article in Academic radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
RATIONALE AND
objectivesPancreatic imaging biomarkers on CT imaging are known to be associated with diabetes. However, no studies have examined if these imaging biomarkers are resilient to changes in segmentation quality and contrast status. Here, we assess if imaging biomarkers are robust to variations in pancreatic segmentation quality and contrast status, and how these factors affect their ability to predict diabetes. MATERIALS AND
methodsThis retrospective study selected patients with CT scans and corresponding HbA1c tests from two institutions. Patients were classified into two categories: having diabetes at the time or < 4 years after the scan (diabetic/incident) vs not having diabetes within 4 years after the scan (nondiabetic). Pancreatic imaging biomarkers, including average attenuation, intrapancreatic fat fraction, fractal dimension of the pancreatic boundary and volume, were measured using three pancreatic segmentation algorithms (TotalSegmentator, nnU-Net, and DM-UNet). Pairwise comparisons were made between algorithms when computing pancreatic imaging biomarker values for all patient scans. Predictive ability of imaging biomarkers (derived from each algorithm) was assessed for agreement between algorithms using a generalized additive model.
resultsA total of 9772 patients (age, 56.1 years ± 9.1 [SD]; 5407 females) were included in this study. Imaging biomarkers based on attenuation measurements showed high algorithm agreement (ICC ≥0.93), with lower agreement on measures not reliant on attenuation. Models trained on imaging biomarkers derived from these algorithms exhibited good predictive agreement (AUC for diabetes overall, 0.84-0.91; contrast scans, 0.73-0.80; noncontrast scans, 0.62-0.80). Algorithms achieved a positive predictive value of 0.79-0.84, and negative predictive value of 0.89-0.94.
conclusionAttenuation-based imaging biomarkers demonstrated robustness to segmentation algorithm quality and consistent predictive ability across different clinical scenarios. These findings suggest that CT-derived biomarkers could be a reliable tool for diabetes screening across multiple institutions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.